Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. (RPHM) Stock Overview
Explore Reneo Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
60.8M
P/E Ratio
65.95
EPS (TTM)
$-16.80
ROE
0.44%
RPHM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Reneo Pharmaceuticals, Inc. (RPHM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 65.95 and a market capitalization of 60.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.